Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.33 |
| ▸ | HTR3B | O95264 | 3/20 | 0.33 |
| ▸ | HTR3A | P46098 | 3/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880338 | 1.00 | LMNA (0.39) | LMNACYP2C9CHRM3OPRK1HTR3E | |
| SCHEMBL23880337 | 1.00 | LMNA (0.39) | LMNACYP2C9CHRM3OPRK1HTR3E | |
| SCHEMBL28515430 | 0.75 | GRM1 (0.35) | — | |
| SCHEMBL29642962 | 0.68 | LMNA (0.41) | LMNACYP2C9CHRM3OPRK1HTR3E | |
| SCHEMBL4128527 | 0.67 | LMNA (0.50) | LMNACYP2C9CHRM3OPRK1HTR3E | |
| SCHEMBL9203936 | 0.67 | HTR3E (0.54) | LMNACYP2C9CHRM3HTR3EHTR3B | |
| SCHEMBL9203933 | 0.67 | HTR3E (0.54) | LMNACYP2C9CHRM3HTR3EHTR3B | |
| SCHEMBL8055978 | 0.66 | GRM1 (0.40) | LMNACYP2C9TDP1CYP2D6MEN1 | |
| SCHEMBL27547000 | 0.64 | MAPT (0.31) | — | |
| SCHEMBL9366512 | 0.63 | MEN1 (0.51) | LMNACYP2C9CHRM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391789-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-07 | — | — | US | disclosed |
| US-11702425-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-07-18 | — | — | US | disclosed |
| US-20210309668-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702425-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | HCCS, PRKAA1, PRKAA2 | LMNA 2153/4885CYP2C9 4416/4885CHRM3 4342/4885 |
| US-20230391789-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | HCCS, PRKAA1, PRKAA2 | LMNA 2153/4885CYP2C9 4416/4885CHRM3 4342/4885 |
| US-20210309668-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | HCCS, PRKAA1, PRKAA2 | LMNA 2153/4885CYP2C9 4416/4885CHRM3 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.